PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study

PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study

Cisplatin-based chemotherapy is the standard treatment for bladder urothelial carcinoma (UC). Most patients experience chemoresistance, the primary cause of treatment failure, which leads to disease relapse. The underlying mechanism of chemoresistance involves reduced apoptosis. In this study, we in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fu-Shun Hsu, Wei-Chou Lin, Kuan-Lin Kuo, Yen-Ling Chiu, Chen-Hsun Hsu, Shih-Ming Liao, Jun-Ren Dong, Shing-Hwa Liu, Shih-Chen Chang, Shao-Ping Yang, Yueh-Tang Chen, Ruei-Je Chang, Kuo-How Huang
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
deubiquitylating enzymes
urothelial carcinoma
chemoresistance
Biology (General)
QH301-705.5
Chemistry
QD1-999
Acceso en línea:https://doaj.org/article/d9994980aac0429085cecb8fda0d6e8e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/d9994980aac0429085cecb8fda0d6e8e

Ejemplares similares